Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned an average recommendation of “Buy” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $13.2471.

Separately, Wedbush dropped their price objective on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th.

Voyager Therapeutics Stock Up 2.1%

Shares of VYGR opened at $3.43 on Friday. The company has a market capitalization of $190.26 million, a price-to-earnings ratio of -1.85 and a beta of 0.90. The stock has a 50 day moving average price of $3.26 and a 200 day moving average price of $3.49. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $8.27.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). The company had revenue of $5.20 million for the quarter, compared to analysts’ expectations of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. On average, equities analysts anticipate that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC grew its holdings in Voyager Therapeutics by 53.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company’s stock valued at $204,000 after buying an additional 21,149 shares during the period. Raymond James Financial Inc. purchased a new stake in Voyager Therapeutics in the 4th quarter valued at about $746,000. Northern Trust Corp grew its holdings in Voyager Therapeutics by 3.0% in the 4th quarter. Northern Trust Corp now owns 418,745 shares of the company’s stock valued at $2,374,000 after buying an additional 12,374 shares during the period. CWM LLC grew its holdings in Voyager Therapeutics by 856.3% in the 1st quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after buying an additional 9,376 shares during the period. Finally, Vestal Point Capital LP grew its holdings in Voyager Therapeutics by 151.0% in the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock valued at $6,974,000 after buying an additional 740,000 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.